The company's UK subsidiary secured National Health Service tenders in three administrative regions immediately upon launch, including northern England, the country's largest procurement zone, where Eydenzelt became the only officially listed biosimilar, Celltrion said Tuesday.
Celltrion has also rolled out Eydenzelt in Portugal, where it plans to target government tenders that account for about 60 percent of the national market. The company aims to progressively expand its European sales footprint through next year to accelerate prescriptions.
"Celltrion, recognized as a biosimilar powerhouse across Europe, plans to leverage its marketing prowess and brand credibility built through years of direct sales to ensure the successful market entry of Eydenzelt," a company official said.
The company intends to tap into existing networks of healthcare professionals established through its portfolio of autoimmune and oncology biosimilars, expecting brand loyalty to carry over to the new ophthalmic product.
Eydenzelt targets the same conditions as Eylea, a treatment for wet age-related macular degeneration and diabetic eye diseases that generated about $9.5 billion in global sales last year. Celltrion obtained European Commission approval for both vial and pre-filled syringe formulations of the biosimilar in February.
The launch is expected to ease healthcare spending burdens across European nations while broadening treatment options for patients suffering from retinal disorders.
Copyright ⓒ Aju Press All rights reserved.
